Catalio Capital Management LP Makes New Investment in Olema Pharmaceuticals, Inc. $OLMA

Catalio Capital Management LP acquired a new position in shares of Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 267,058 shares of the company’s stock, valued at approximately $6,676,000. Catalio Capital Management LP owned 0.39% of Olema Pharmaceuticals as of its most recent filing with the Securities & Exchange Commission.

Other large investors also recently added to or reduced their stakes in the company. EverSource Wealth Advisors LLC raised its position in Olema Pharmaceuticals by 9,476.9% during the fourth quarter. EverSource Wealth Advisors LLC now owns 1,245 shares of the company’s stock worth $31,000 after acquiring an additional 1,232 shares during the period. Torren Management LLC acquired a new position in Olema Pharmaceuticals during the fourth quarter worth $44,000. Russell Investments Group Ltd. acquired a new position in Olema Pharmaceuticals during the third quarter worth $53,000. American Century Companies Inc. acquired a new position in Olema Pharmaceuticals during the second quarter worth $54,000. Finally, Creative Planning acquired a new position in Olema Pharmaceuticals during the second quarter worth $83,000. 91.78% of the stock is currently owned by institutional investors and hedge funds.

Olema Pharmaceuticals Price Performance

Olema Pharmaceuticals stock opened at $9.44 on Thursday. Olema Pharmaceuticals, Inc. has a 52-week low of $3.90 and a 52-week high of $36.26. The firm has a market capitalization of $824.58 million, a price-to-earnings ratio of -4.67 and a beta of 1.98. The company has a fifty day simple moving average of $13.62 and a 200-day simple moving average of $20.16. The company has a quick ratio of 10.88, a current ratio of 10.88 and a debt-to-equity ratio of 0.01.

Olema Pharmaceuticals (NASDAQ:OLMA) last released its earnings results on Tuesday, May 12th. The company reported ($0.52) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.52). On average, equities analysts anticipate that Olema Pharmaceuticals, Inc. will post -2.22 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on OLMA. Jefferies Financial Group began coverage on shares of Olema Pharmaceuticals in a report on Thursday, March 19th. They set a “buy” rating and a $40.00 target price for the company. Wolfe Research began coverage on shares of Olema Pharmaceuticals in a report on Friday, March 27th. They set a “peer perform” rating for the company. Wall Street Zen raised shares of Olema Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Monday, April 27th. Oppenheimer reaffirmed an “outperform” rating on shares of Olema Pharmaceuticals in a report on Monday, March 9th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Olema Pharmaceuticals in a report on Tuesday, April 21st. Eleven analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $44.10.

About Olema Pharmaceuticals

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.